Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03852719
Study type Interventional
Source Gilead Sciences
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 17, 2019
Completion date July 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04170452 - Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
Completed NCT03852433 - Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) Phase 2
Withdrawn NCT05953545 - Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Phase 2